Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.

Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE.

Sci Transl Med. 2014 Feb 12;6(223):223ra23. doi: 10.1126/scitranslmed.3007811.

2.

Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.

Agarwal P, Rashighi M, Essien KI, Richmond JM, Randall L, Pazoki-Toroudi H, Hunter CA, Harris JE.

J Invest Dermatol. 2015 Apr;135(4):1080-8. doi: 10.1038/jid.2014.529. Epub 2014 Dec 18.

3.

A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin.

Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA.

J Invest Dermatol. 2012 Jul;132(7):1869-76. doi: 10.1038/jid.2011.463. Epub 2012 Feb 2.

4.

CXCR3-mediated skin homing of autoreactive CD8 T cells is a key determinant in murine graft-versus-host disease.

Villarroel VA, Okiyama N, Tsuji G, Linton JT, Katz SI.

J Invest Dermatol. 2014 Jun;134(6):1552-60. doi: 10.1038/jid.2014.2. Epub 2014 Jan 3.

5.

Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse.

Kim J, Choi JY, Park SH, Yang SH, Park JA, Shin K, Lee EY, Kawachi H, Kohsaka H, Song YW.

Arthritis Res Ther. 2014 Jun 17;16(3):R126. doi: 10.1186/ar4583.

6.

Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo.

You S, Cho YH, Byun JS, Shin EC.

Clin Exp Immunol. 2013 Oct;174(1):38-44. doi: 10.1111/cei.12146.

7.

NOD2 regulates CXCR3-dependent CD8+ T cell accumulation in intestinal tissues with acute injury.

Wu X, Lahiri A, Haines GK 3rd, Flavell RA, Abraham C.

J Immunol. 2014 Apr 1;192(7):3409-18. doi: 10.4049/jimmunol.1302436. Epub 2014 Mar 3.

8.

Role of CXCR3/CXCL10 axis in immune cell recruitment into the small intestine in celiac disease.

Bondar C, Araya RE, Guzman L, Rua EC, Chopita N, Chirdo FG.

PLoS One. 2014 Feb 20;9(2):e89068. doi: 10.1371/journal.pone.0089068. eCollection 2014.

9.

Increased Expression of CXCR3 and its Ligands in Vitiligo Patients and CXCL10 as a Potential Clinical Marker for Vitiligo.

Wang X, Wang Q, Wu J, Jiang M, Chen L, Zhang C, Xiang L.

Br J Dermatol. 2016 Jan 23. doi: 10.1111/bjd.14416. [Epub ahead of print]

PMID:
26801009
10.

Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases.

Tacke F, Zimmermann HW, Berres ML, Trautwein C, Wasmuth HE.

Liver Int. 2011 Jul;31(6):840-9. doi: 10.1111/j.1478-3231.2011.02504.x. Epub 2011 Mar 10.

PMID:
21645215
11.

Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice.

Santodomingo-Garzon T, Han J, Le T, Yang Y, Swain MG.

Hepatology. 2009 Apr;49(4):1267-76. doi: 10.1002/hep.22761.

PMID:
19140218
12.

CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease.

Wenzel J, Lucas S, Zahn S, Mikus S, Metze D, Ständer S, von Stebut E, Hillen U, Bieber T, Tüting T.

J Am Acad Dermatol. 2008 Mar;58(3):437-42. doi: 10.1016/j.jaad.2007.10.647.

PMID:
18280341
13.
14.

Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice.

Ikeda A, Aoki N, Kido M, Iwamoto S, Nishiura H, Maruoka R, Chiba T, Watanabe N.

Hepatology. 2014 Jul;60(1):224-36. doi: 10.1002/hep.27087. Epub 2014 May 28.

PMID:
24700550
15.

Expression of CXCR3 and its ligands CXCL9, -10 and -11 in paediatric opsoclonus-myoclonus syndrome.

Pranzatelli MR, Tate ED, McGee NR, Travelstead AL, Verhulst SJ, Ransohoff RM.

Clin Exp Immunol. 2013 Jun;172(3):427-36. doi: 10.1111/cei.12065.

16.

[Expression and significance of chemokine CXC receptor 3, 4 and their ligands at the early pregnancy decidua and villi].

Bai XX, Kong BH, Zhang YZ, Qu X, Wang HL.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):904-8. Chinese.

PMID:
19134328
17.

Type I interferon signature in the initiation of the immune response in vitiligo.

Bertolotti A, Boniface K, Vergier B, Mossalayi D, Taieb A, Ezzedine K, Seneschal J.

Pigment Cell Melanoma Res. 2014 May;27(3):398-407. doi: 10.1111/pcmr.12219. Epub 2014 Feb 21.

PMID:
24438589
18.

Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis.

Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK 3rd, Impens AJ, Phillips K, Kahaleh B, Seibold JR, Koch AE.

Arthritis Res Ther. 2011 Feb 8;13(1):R18. doi: 10.1186/ar3242.

19.

Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria.

Campanella GS, Tager AM, El Khoury JK, Thomas SY, Abrazinski TA, Manice LA, Colvin RA, Luster AD.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4814-9. doi: 10.1073/pnas.0801544105. Epub 2008 Mar 17.

20.

CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease.

Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, Lu B, Farber J, Luster AD, Kelley VR.

J Am Soc Nephrol. 2008 Jun;19(6):1177-89. doi: 10.1681/ASN.2007111179. Epub 2008 Mar 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk